Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
40 studies found for:    myeloma and carfilzomib | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support
Condition: Multiple Myeloma
Interventions: Drug: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan;   Drug: Carfilzomib/dexamethasone maintenance;   Drug: Observation without carfilzomib/dexamethasone maintenance
2 Recruiting A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
3 Recruiting A Single Arm Study of Carfilzomib in Transplant Eligible High Risk Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib, Cyclophosphamide, Dexamethasone
4 Recruiting Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
5 Recruiting A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
6 Recruiting Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Prednisone;   Drug: Methylprednisolone
7 Recruiting Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Carfilzomib;   Drug: Dexamethasone
8 Recruiting Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: carfilzomib;   Drug: dexamethasone
9 Recruiting Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Carfilzomib;   Drug: Dexamethasone
10 Not yet recruiting Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Selinexor;   Drug: Placebo (for selinexor);   Drug: carfilzomib;   Drug: Dexamethasone
11 Not yet recruiting Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: Venetoclax;   Drug: Dexamethasone;   Drug: Carfilzomib
12 Recruiting High Dose Carfilzomib for Newly Diagnosed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
13 Not yet recruiting Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Condition: Multiple Myeloma
Interventions: Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
14 Recruiting Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Intervention: Drug: Carfilzomib
15 Recruiting Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Cohort 1: Carfilzomib 15 mg/m2;   Drug: Cohort 2: Carfilzomib 20 mg/m2;   Drug: Cohort 2b: Carfilzomib 20 mg/m2;   Drug: Cohort 3b: Carfilzomib 27 mg/m2
16 Recruiting High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
17 Recruiting Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: pegylated liposomal doxorubicin (PLD);   Drug: Dexamethasone
18 Recruiting Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
19 Recruiting SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: SAR650984;   Drug: Carfilzomib
20 Recruiting Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.